Could Cara Therapeutics, Inc. Be a Millionaire-Maker Stock? [The Motley Fool]
Cara Therapeutics, Inc. (CARA)
Last cara therapeutics, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.caratherapeutics.com/investor-relations
Company Research
Source: The Motley Fool
Could Cara be the answer for investors itching to make $1 million? You've probably heard the expression no pain, no gain. In Cara Therapeutics ' ( NASDAQ:CARA ) case, it's more like no pain, big gain. The biotech's lead candidate, CR845, is in a late-stage study for relief of post-operative pain. CR845 is also in another late-stage study for treatment of chronic kidney disease-associated pruritus (CKD-aP), a chronic itching experienced by many patients on dialysis. Good news from those studies should send Cara stock through the roof. But could Cara Therapeutics really be a millionaire-maker stock? Let's take a look. Image source: Getty Images. The opportunities Several months ago, I wrote about two possibilities for where Cara Therapeutics could be in five years . In the dream scenario, the biotech would report stellar results from its phase 3 post-operative pain study in the first half of this year. That would lead to a regulatory filing for the intraveno
Show less
Read more
Impact Snapshot
Event Time:
CARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CARA alerts
High impacting Cara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CARA
News
- Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Uremic Pruritus Pipeline Insight 2024, Featuring Key Players Cara Therapuetics and Lumosa Therapeutics, and Key Emerging Drugs Cara Therapeutics CR845 and Lumos Therapeutics' LT 5001 [Yahoo! Finance]Yahoo! Finance
- Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.MarketBeat
- Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.MarketBeat
CARA
Earnings
- 3/4/24 - Beat
CARA
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form ARS
- 4/22/24 - Form DEF
- CARA's page on the SEC website